Tirzepatide: How a Dual Agonist Raised the Ceiling on Weight-Loss Medicine

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide, loosely modelled on the gut hormone GIP and engineered to activate both the GIP and GLP-1 receptors. Eli Lilly developed it as a once-weekly injection; a fatty-acid chain bound to the peptide lets it hitch a ride on albumin in the blood, stretching its half-life to about five days.

Unlike most compounds in the peptide conversation, tirzepatide is an actual medicine. It is prescribed in Canada as Mounjaro for type 2 diabetes, and regulators including Health Canada have authorized it for chronic weight management (marketed as Zepbound in the U.S.). That authorization attaches to specific manufactured products, not to any vial with “tirzepatide” on the label.

Why researchers are interested

Tirzepatide mimics two incretins, GLP-1 and GIP, hormones released from the gut after eating that amplify insulin secretion when glucose is high. GLP-1 receptor agonists were already proven medicine; the surprise was GIP. On its own, GIP agonism looked unimpressive, and some researchers had even pursued GIP *antagonism* for obesity. Combined with GLP-1 activity in one molecule, though, the pairing outperformed GLP-1 alone on both glucose and weight in clinical trials.

Mechanistically, the GLP-1 arm slows gastric emptying and acts on appetite circuits in the hypothalamus and brainstem, while the GIP arm appears to act on adipose tissue and possibly on brain regions that reduce nausea, one proposed explanation for why tirzepatide's higher doses remained tolerable. The full story of what GIP contributes is, genuinely, still being worked out even as the drug is prescribed to millions.

Regulatory status

Tirzepatide is authorized in Canada, the U.S., Europe, and elsewhere for type 2 diabetes and for chronic weight management, in each case as a specific product from a specific manufacturer with defined indications and prescribing information. Access is by prescription, with medical supervision built into the deal.

What human research shows

Few molecules arrive with this much randomized evidence. The SURPASS programme tested tirzepatide across thousands of people with type 2 diabetes, showing greater reductions in blood glucose than comparators including insulin and, notably, semaglutide 1 mg in a head-to-head trial. The SURMOUNT programme then tested it for obesity: in SURMOUNT-1, average weight loss at the highest dose was around a fifth of body weight over 72 weeks. That is territory previously reserved for bariatric surgery.

Subsequent trials extended the picture: benefits for obstructive sleep apnea in people with obesity, and a head-to-head obesity trial against semaglutide in which tirzepatide produced greater average weight loss. The main adverse effects are gastrointestinal: nausea, vomiting, constipation, and diarrhea, typically worst during dose escalation. These findings apply to the authorized products used as prescribed; they do not transfer to grey-market copies.

What early research shows

Preclinical work on tirzepatide established the dual-agonist rationale: in rodent models, combined GIP/GLP-1 activity improved weight and glycemic outcomes beyond GLP-1 alone. The animal work continues to probe unanswered mechanistic questions, such as exactly where GIP acts in the brain. At this point the animal data mostly refines understanding of a drug whose human effects are already well documented, a rare and pleasant inversion of the usual situation on this list.

What it's being studied for

Tirzepatide's trial pipeline did not stop at approval. Researchers are investigating:

• Long-term cardiovascular outcomes in people with obesity
• Heart failure with preserved ejection fraction
• Metabolic dysfunction-associated steatotic liver disease
• Weight-loss maintenance and what happens after discontinuation
• Effects on body composition, including lean-mass preservation
• Chronic kidney disease outcomes

What remains uncertain

For tirzepatide, duration is the big one: these drugs appear to require ongoing use, and trials consistently show weight regain after stopping. How many years, or decades, of continuous use are safe is unknowable until those years pass. The proportion of lost weight that comes from muscle rather than fat, and what that means for older adults, is an active worry in the longevity field.

There are also open questions about rare harms across the incretin class, and a practical one specific to the hype cycle: shortages and cost have pushed people toward compounded and counterfeit versions whose contents nobody has verified.

What people report

Patient reports on tirzepatide are broadly consistent with the trials. Reduced appetite, early satiety, the disappearance of constant food preoccupation, plus the less glamorous parts: nausea, fatigue, and “sulfur burps” that trial tables record drily as eructation. Because the drug is usually started alongside dietary changes and medical supervision, individuals often can't untangle what the molecule did from what the lifestyle overhaul did.

Here, at least, the anecdotes sit on top of randomized evidence rather than in place of it. That is the difference between tirzepatide and nearly everything else in this section.

Sources

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.